线粒体改变与慢性肾脏病:综述
本综述聚焦线粒体改变在糖尿病和非糖尿病慢性肾脏病(CKD)发病机制中的核心作用,涵盖生物能量学、动力学、氧化还原平衡及生物合成变化。文章汇总了高分辨呼吸测定、代谢组学、转录组学及功能MRI/PET等线粒体健康评估方法,并讨论SGLT2抑制剂、GLP-1受体激动剂、非甾体盐皮质激素受体拮抗剂及NAD+增强剂、辅酶Q10衍生物等靶向线粒体通路药物的前景。多组学整合与空间 profiling 有望实现线粒体健康评分指导的个体化治疗。
要点
- 线粒体改变参与糖尿病和非糖尿病CKD的能量代谢障碍与氧化应激。
- 高分辨呼吸测定、代谢组学及功能MRI/PET可用于评估线粒体健康。
- SGLT2抑制剂、GLP-1 RA、nsMRAs等药物可调节线粒体通路。
核心结论
- 靶向线粒体适应是改善CKD结局的有前景途径。
研究设计与样本
- 综述,总结线粒体重塑在糖尿病和非糖尿病CKD中的研究进展及评估与治疗手段。
主要发现
- 线粒体改变涉及生物能量学、动力学、氧化还原平衡和生物合成。
- 高分辨呼吸测定、代谢组学、转录组学及功能MRI/PET可用于线粒体健康评估。
- SGLT2抑制剂、GLP-1 RA、nsMRAs及NAD+增强剂、辅酶Q10衍生物等显示调节线粒体通路的潜力。
临床怎么用
- 多组学整合与空间 profiling 可支持线粒体健康评分指导的个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitochondrial alterations are increasingly recognized as central to the pathogenesis of chronic kidney disease (CKD), contributing to impaired energy metabolism, oxidative stress, and maladaptive cellular responses. This review highlights recent advances in our understanding of mitochondrial remodeling in both diabetic and nondiabetic CKD (NDKD), including changes in bioenergetics, dynamics, redox balance, and biogenesis. We discuss state-of-the-art approaches to assess mitochondrial health, ranging from high-resolution respirometry and metabolomic profiling to transcriptomic analysis and advanced imaging techniques such as functional magnetic resonance imaging (MRI) and positron emission tomography (PET) radiotracers with metabolic readouts. Therapeutically, several agents show promise in modulating mitochondrial pathways, including sodium/glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RA), and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), as well as emerging interventions such as glucose-dependent insulinotropic polypeptide and glucagon receptor agonist, nicotinamide adenine dinucleotide (NAD+) boosters, and coenzyme Q10 (CoQ10) derivatives. Multi-omics integration and spatial profiling are enabling precision phenotyping and the development of mitochondrial health scores to guide individualized therapy. Targeting mitochondrial adaptation offers a compelling avenue to improve outcomes in CKD.
引用
- Pinzon-Cortes JA, Narongkiatikhun P, Yuan L, et al. Mitochondrial Alterations and CKD: A Review. Am J Kidney Dis. 2026. PMID: 42331132. doi:10.1053/j.ajkd.2026.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。